EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Kinnosuke Matsumoto iD, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya iD, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki und 9 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70336 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Kinnosuke Matsumoto und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Docetaxel. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death‐1 (PD‐1) inhibitors in advanced non‐small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit‐associated biomarkers. Patients treated with RAM+DOC after PD‐1 inhibitors were enrolled in a multicenter prospective cohort. Anti‐PD‐1 antibody bound (IgG4 + ) T‐cell subsets were measured at baseline (T0) and after 2–3 cycles (T1), reflecting residual anti‐PD‐1 antibody binding on circulating T cells. T1/T0 ratios of immune subsets were calculated to assess dynamics. Landmark analyses at T1 evaluated associations with progression‐free survival (PFS) and overall survival (OS). Prognostic biomarkers were assessed at baseline. Among 27 evaluable patients, the objective response rate was 37.0%, median PFS 5.1 months, and OS 10.4 months. RAM + DOC responders had higher IgG4 + CD8 + T‐cell and lower IgG4 + Treg T1/T0 ratios (both p < 0.001). Higher IgG4 + CD8 + ratios were associated with longer landmark PFS ( p = 0.002) and OS ( p = 0.016) and were inversely correlated with IgG4 + Treg ratios ( p = 0.008). Among the baseline factors, high IgG4 + CD8 + Temra conferred survival benefits (OS, not reached vs. 8.2 months; p = 0.006), and low vascular endothelial growth factor (VEGF)‐C levels were associated with longer OS (not reached vs. 8.5 months, p = 0.044). Both variables remained independent prognostic factors of PFS and OS in multivariable analysis. Our findings suggest that sequential strategy administering RAM+DOC during persistent binding of anti–PD‐1 antibody to T cells may be beneficial. IgG4 + CD8 + Temra and VEGF‐C levels at RAM+DOC initiation may serve as biomarkers of survival benefit. Trial Registration: UMIN‐Clinical Trials Registry (UMIN000050478)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDocetaxelImmune Checkpoint InhibitorsLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorProgression-Free SurvivalProspective StudiesRamucirumabTreatment Outcome

Stichwörter der Autor:innen

NSCLCnivolumabpembrolizumabramucirumabsequential

Substanzen

Antibodies, Monoclonal, HumanizedDocetaxelImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRamucirumab

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Signal Transduction, Research Institute for Microbial Diseases, The University of Osaka, Osaka, Japan.
  • Department of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, Japan.
  • Department of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital, Osaka, Japan.
  • Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.

ORCID-Profile: Kinnosuke Matsumoto, Akihiro Tamiya, Toshiyuki Minami, Shohei Koyama, Nobuyuki Takakura

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Eli Lilly Japan
  • Japan Science and Technology Agency
  • Support for Pioneering Research Initiated by the Next Generation

Zitieren

APA

Matsumoto, K., Naito, Y., Shiroyama, T., Tamiya, M., Nishino, K., Tamiya, A., Okishio, K., Kinehara, Y., Kuge, T., Mori, M., Satoh, S., Suzuki, H., Tetsumoto, S., Niki, T., Suga, Y., Osa, A., Minami, T., Koyama, S., Takeda, Y., …, & Kumanogoh, A. (2026). Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes. Cancer Science. https://doi.org/10.1111/cas.70336

Vancouver

Matsumoto K, Naito Y, Shiroyama T, Tamiya M, Nishino K, Tamiya A, et al. Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes. Cancer Science. 2026. doi:10.1111/cas.70336

BibTeX
@article{Matsumoto2026,
  author = {Matsumoto, Kinnosuke and Naito, Yujiro and Shiroyama, Takayuki and Tamiya, Motohiro and Nishino, Kazumi and Tamiya, Akihiro and Okishio, Kyoichi and Kinehara, Yuhei and Kuge, Tomoki and Mori, Masahide and Satoh, Shingo and Suzuki, Hidekazu and Tetsumoto, Satoshi and Niki, Toshie and Suga, Yasuhiko and Osa, Akio and Minami, Toshiyuki and Koyama, Shohei and Takeda, Yoshito and Takakura, Nobuyuki and Kumanogoh, Atsushi},
  title = {Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70336}
}
Kostenlos starten →